912 related articles for article (PubMed ID: 25689584)
1. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
2. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
3. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
[TBL] [Abstract][Full Text] [Related]
4. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
5. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
6. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
[TBL] [Abstract][Full Text] [Related]
8. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Aldoss I; Ji L; Haider M; Pullarkat V
Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
[TBL] [Abstract][Full Text] [Related]
9. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
10. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
11. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
13. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
14. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
15. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Ahmed T; Holwerda S; Klepin HD; Isom S; Ellis LR; Lyerly S; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee TS
Leuk Res; 2015 Sep; 39(9):945-9. PubMed ID: 26154683
[TBL] [Abstract][Full Text] [Related]
16. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia.
Schiller G; Emmanoulides C; Iastrebner MC; Lee M; Naeim F
Leuk Lymphoma; 1996 Feb; 20(5-6):427-34. PubMed ID: 8833398
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
19. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
20. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
